GENERAL11 Sept 2026
Alembic Pharma clears USFDA inspection at Vadodara bioequivalence facility
Alembic Pharmaceuticals got a clean result at its Vadodara bioequivalence facility. The USFDA (US Food and Drug Administration) finished an unannounced inspection on 10 September 2026 with no Form 483 observations. That form is issued when inspectors spot possible violations, so zero observations means no compliance issues were flagged. If you supply or invest in pharma, treat this as a good sign for the company's US filings.
Key Statutory Highlights
- Alembic Pharmaceuticals said the USFDA completed an unannounced inspection at its bioequivalence facility in Vadodara, Gujarat.
- The company said the onsite bioequivalence inspection ran from August 31, 2026, to September 10, 2026.
- The inspection concluded with no Form 483 observations, which the company described as a clean outcome.
Actionable Advice for Taxpayers / Founders:If you hold Alembic shares or depend on it as a supplier, read the company's regulatory filing and watch for any follow-up disclosures before you act. This news alone is not a guarantee of future US approvals, so check with your advisor before making any decision.
Statutory Disclaimer: TaxQue Shorts are AI-assisted editorial briefs for compliance awareness. This brief has not passed every source check; confirm the original notification before acting. This does not constitute formal legal or CA counsel.
TaxQue News Desk
Share: